MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Amphastar Pharmaceuticals Operating Expenses 2011-2025 | AMPH
Annual Operating Expenses Amphastar Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 168 M | 154 M | 141 M | 130 M | 132 M | 132 M | 116 M | 94.3 M | 88.5 M | 84 M | 68.8 M | 69.3 M | 62.8 M | 61.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 168 M | 61.6 M | 107 M |
Quarterly Operating Expenses Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 73.3 M | 44.3 M | 48 M | - | 44.9 M | 39.9 M | 42.1 M | - | 35.7 M | 35.8 M | 40.4 M | - | 35.3 M | 38.5 M | 34.2 M | - | 26.4 M | 36.8 M | 34.6 M | - | 33 M | 36.1 M | 29.3 M | - | 32.8 M | 31.4 M | 34.1 M | - | 26.7 M | 29 M | 26.7 M | - | 23.5 M | 24.6 M | 21.4 M | - | 21.8 M | 21.4 M | 20.8 M | - | 21.3 M | 23.6 M | 20.5 M | - | 19.6 M | 16.2 M | 14.5 M | - | 20.1 M | 15.5 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.3 M | 14.5 M | 30.9 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
12.8 B | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
BioVie
BIVI
|
18.1 M | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Axon Enterprise
AXON
|
1.18 B | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Biogen
BIIB
|
5.39 B | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.29 | -5.01 % | $ 631 M |  Israel |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Benitec Biopharma
BNTC
|
9.83 M | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Enochian Biosciences
ENOB
|
189 M | - | - | $ 40.5 M | USA |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cerus Corporation
CERS
|
135 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.15 | -0.44 % | $ 1.47 B | Britain |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
Cellectar Biosciences
CLRB
|
15.3 M | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
12.2 B | $ 51.05 | -0.32 % | $ 103 B | USA |
 |
Abeona Therapeutics
ABEO
|
50.6 M | $ 5.5 | 0.46 % | $ 118 M | USA |
 |
ADiTx Therapeutics
ADTX
|
27.4 M | $ 2.36 | -7.29 % | $ 31.1 K | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 2.1 | -4.34 % | $ 5.32 M | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.42 | 6.77 % | $ 134 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 3.22 | -2.72 % | $ 908 M | Israel |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Baudax Bio
BXRX
|
54.6 M | - | 0.59 % | $ 63 K | USA |
 |
Завод ДИОД
DIOD
|
249 M | - | - | - | Russia |